Kyphon Newswire (Page 7)

Comprehensive Real-Time News Feed for Kyphon. (Page 7)

Results 121 - 140 of 804 in Kyphon

  1. Ten minutes with Nashville's newest public company CEORead the original story w/Photo

    Dec 29, 2014 | Business Journal

    Symmetry Surgical, a surgical device company that was formerly a subsidiary of Indiana-based Symmetry Medical headquartered in Antioch, spun out as its own publicly traded company at the start of December, following a transaction in which its parent company sold to a private equity firm. Last week, CEO Tom Sullivan and other members of the Symmetry Surgical team marked the occasion by ringing the bell at the Nasdaq MarketSite in Times Square.

    Comment?

  2. Comparing America's 3 Largest Medical Appliances & Equipment CompaniesRead the original story w/Photo

    Dec 29, 2014 | Seeking Alpha

    The Medical Appliances & Equipment industry is expected to outperform the S&P broader market astronomically this quarter, negligibly next quarter, and significantly in 2015 and beyond. Mean/high targets for the 3 largest U.S. Medical Appliances & Equipment companies - Medtronic Inc., Stryker Corporation, Zimmer Holdings - range from 1% below to 31% above current prices.

    Comment?

  3. After Medtronic merger, IRS bill looms for shareholdersRead the original story w/Photo

    Dec 27, 2014 | TwinCities

    Shareholder Jim Wychor of Mounds View asked a tax question of CEO Omar Ishak at Medtronic's annual meeting at the company's headquarters in Mounds View, Mn. on Thursday, August 21, 2014.

    Comment?

  4. Medtronic: Estimated Intrinsic Value Of $88-111Read the original story w/Photo

    Dec 26, 2014 | Seeking Alpha

    Having previously estimated an intrinsic value of $70-88 for Medtronic , I revise my target upwards to $88-111 due to a strong cash flow position and higher P/E ratio. With a payout ratio of 30% and 36 consecutive years of dividend increases, Medtronic appears highly attractive as an income-yielding stock.

    Comment?

  5. Local biotech to push a partner system it hopes makes its drug easier to takeRead the original story w/Photo

    Dec 26, 2014 | Business Journal

    United Therapeutics, founded and led by co-CEO Martine Rothblatt, hopes to get federal approval for an implantable drug infusion system to use with its pulmonary hypertension drug. The Silver Spring biotech said a partner company has applied for premarket approval from federal regulators to allow patients to use United Therapeutics' flagship injectable drug, Remodulin, with an implantable drug infusion system called SynchroMed II.

    Comment?

  6. Year in review: The biggest stories in biotech in 2014Read the original story w/Photo

    Dec 26, 2014 | Business Journal

    Merger mania : Covidien , Idenix and Cubist all were or are in the process of being acquired in multi-billion dollar deals. The acquisition of Cambridge-based Idenix Pharmaceuticals by Merck & Co.

    Comment?

  7. United Therapeutics submits pre-market approval application for use...Read the original story w/Photo

    Dec 25, 2014 | Medical News

    United Therapeutics Corporation announced today that Medtronic, Inc. has submitted a pre-market approval application to the U.S. Food and Drug Administration for the use of Medtronic's SynchroMedA II implantable drug infusion system for use with United Therapeutics' RemodulinA Injection delivered intravenously to patients with pulmonary arterial hypertension.

    Comment?

  8. United Therapeutics Announces Submission Of Pre-Market Approval...Read the original story

    Dec 24, 2014 | PressReleasePoint

    United Therapeutics Corporation announced today that Medtronic, Inc. has submitted a pre-market approval application to the U.S. Food and Drug Administration for the use of Medtronic's SynchroMedA II implantable drug infusion system for use with United Therapeutics' RemodulinA Injection delivered intravenously to patients with pulmonary arterial hypertension. United Therapeutics plans to submit to the FDA a supplement to its New Drug Application for Remodulin in January 2015, in order to amend Remodulin's labeling to support the use of the drug with the SynchroMed II implantable drug infusion system.

    Comment?

  9. Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops...Read the original story

    Dec 22, 2014 | PR-inside.com

    Results of IN.PACT SFA Trial Published in Circulation MINNEAPOLIS -- Dec. 22, 2014 -- The results of a landmark study published this month in Circulation, the world's leading cardiovascular journal, indicate that a novel medical device from Medtronic, Inc. called the IN.PACT Admiral drug-coated balloon significantly outperformed standard balloon angioplasty in the treatment of symptomatic peripheral artery disease in the upper leg -- specifically, the superficial femoral and proximal popliteal arteries.

    Comment?

  10. Medtronic, St. Jude roll out enhanced devices to restore normal heart rhythmsRead the original story w/Photo

    Dec 20, 2014 | Star Tribune

    When shocking an out-of-sync heart, having more points of electrical contact between a device and the patient gives doctors better options to force a failing cardiac muscle to beat in rhythm again. That's why competition continues to mount among medical device companies in the $3 billion global market for cardiac resynchronization A therapy systems, balancing maximum flexibility in the operating room against the long-term battery life of an implanted device.

    Comment?

  11. 3-D Printing Is Not Just Cool, It's Cost Effective TooRead the original story w/Photo

    Dec 18, 2014 | Medical Device/Diagnostic Ind.

    Then there is Oxford Performance Materials' 3-D printed cranial and facial implants - both FDA-approved - and the former was used to replace 75% of a patient's skull. But with rapid advances in technology which has lowered the price of 3-D printing, the technology can be very cost-effective too, especially in the prototype phase and even doing small manufacturing runs.

    Comment?

  12. Deal reached in St. Anthony Islamic Center disputeRead the original story w/Photo

    Dec 16, 2014 | Star Tribune

    The U.S. attorney's office in Minneapolis has scheduled a news conference at 1:30 p.m. Tuesday to announce the details. The federal government sued the small north-metro city in August, contending that its City Council violated federal law in 2012 by rejecting a proposed Islamic center.

    Comment?

  13. Medtronic Receives FDA Approval and Launches Two New Cardiac...Read the original story

    Dec 11, 2014 | PressReleasePoint

    Additional Attain PerformaA Quadripolar Leads Provide Physicians with More Options to Optimize Delivery of Proven Heart Failure Treatment MINNEAPOLIS - Dec. 11, 2014 - Medtronic, Inc. today announced the U.S. Food and Drug Administration approval and commercial launch of two additional Attain PerformaA left ventricular quadripolar leads, which can be paired with the Medtronic VivaA Quad XT and VivaA Quad S cardiac resynchronization therapy defibrillators to treat patients with heart failure. The newest additions to the Attain Performa lead portfolio, the S-shape and Straight leads, are designed to accommodate patients' varying vessel sizes and curvatures to enhance successful lead placement.

    Comment?

  14. Medtronic to Exhibit Latest Advancements in Spinal Cord Stimulation...Read the original story

    Dec 11, 2014 | PressReleasePoint

    Highlighting the Evolution of High-Density Programming with Adaptive Stimulation MINNEAPOLIS - December 11, 2014 - Medtronic, Inc. will exhibit a variety of innovations focused on providing patients with better pain relief and improving the overall patient experience during the North American Neuromodulation Society's annual meeting, December 11-14, 2014, in Las Vegas.

    Comment?

  15. Medtronic Receives FDA Approval and Launches Two New Cardiac...Read the original story

    Dec 11, 2014 | PR-inside.com

    Additional Attain PerformaA Quadripolar Leads Provide Physicians with More Options to Optimize Delivery of Proven Heart Failure Treatment MINNEAPOLIS - Dec. 11, 2014 - Medtronic, Inc. today announced the U.S. Food and Drug Administration approval and commercial launch of two additional Attain PerformaA left ventricular quadripolar leads, which can be paired with the Medtronic VivaA Quad XT and VivaA Quad S cardiac resynchronization therapy defibrillators to treat patients with heart failure. The newest additions to the Attain Performa lead portfolio, the S-shape and Straight leads, are designed to accommodate patients' varying vessel sizes and curvatures to enhance successful lead placement.

    Comment?

  16. 0 commentRead the original story

    Dec 9, 2014 | Roseville Review

    The former Medtronic headquarters at 3055 Old Highway 8 is at the center of a federal civil rights lawsuit against St. Anthony. The U.S. Justice Department sued the city after it denied a conditional use permit that would have allowed worship at an Islamic center in the building.

    Comment?

  17. Meeting set on federal civil rights lawsuit against St. Anthony over denial of Islamic centerRead the original story

    Dec 9, 2014 | Roseville Review

    The former Medtronic headquarters at 3055 Old Highway 8 is at the center of a federal civil rights lawsuit against St. Anthony. The U.S. Justice Department sued the city after it denied a conditional use permit that would have allowed worship at an Islamic center in the building.

    Comment?

  18. Endurant 'AAA' Stent Graft from Medtronic Continues to...Read the original story

    Dec 9, 2014 | PR-inside.com

    Latest Results from Two Clinical Studies Show Strong Mid-Term Performance of Leading Medical Device for Endovascular Repair of Abdominal Aortic Aneurysms MINNEAPOLIS -- Dec. 9, 2014 -- For endovascular repair of abdominal aortic aneurysms, the Endurant AAA stent graft system from Medtronic, Inc. continues to deliver durable, consistent and proven outcomes, according to the latest results from two clinical studies. The Endurant AAA stent graft system has been used to treat more than 165,000 patients worldwide since it was initially introduced in Europe in 2008 -- more than any other device of its kind, being selected for nearly one of every two endovascular procedures to repair abdominal aortic aneurysms around the world.

    Comment?

  19. Medtronic giving the gift of cash to San Antonio health organizationsRead the original story w/Photo

    Dec 8, 2014 | Business Journal

    Minneapolis-based Medtronic Inc., which operates a campus in San Antonio, is contributing $250,000 in Health Access Grants to five San Antonio area organizations. The grants come as Medtronic celebrates its five-year anniversary in San Antonio.

    Comment?

  20. Medtronic Issues $250,000 in Health Access Grants to Support Diabetes ...Read the original story

    Dec 8, 2014 | PressReleasePoint

    Grants Help Mark Five Years Since Diabetes Therapy Management and Education Center Opened its Doors SAN ANTONIO, TX - December 8, 2014 - Medtronic, Inc. today announced that five San Antonio community organizations will receive a combined $250,000 in Health Access Grants in recognition of their continued commitment to promoting healthy lifestyles and improving access to healthcare, with an emphasis on diabetes. As Medtronic marks the five year anniversary of its San Antonio location, this announcement demonstrates the company's ongoing support of the local community.

    Comment?